CUSIP: 88369M101
Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
40,020,151
-
Share change
-
+509,901
-
Total reported value
-
$373,623,972
-
Price per share
-
$9.33
-
Number of holders
-
69
-
Value change
-
+$6,179,224
-
Number of buys
-
37
-
Number of sells
-
26
Quarterly Holders Quick Answers
What is CUSIP 88369M101?
CUSIP 88369M101 identifies THRX - THESEUS PHARMACEUTICALS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2023
-
Previous quarter:
Q1 2023
Recent filing periods for CUSIP 88369M101:
Institutional Holders of THESEUS PHARMACEUTICALS INC - COM (THRX) as of Q2 2023
As of 30 Jun 2023,
THESEUS PHARMACEUTICALS INC - COM (THRX) was held by
69 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
40,020,151 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, Foresite Capital Management V, LLC, Frazier Life Sciences Management, L.P., Paradigm Biocapital Advisors LP, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), BlackRock Inc., PRICE T ROWE ASSOCIATES INC /MD/, FMR LLC, VR Adviser, LLC, and Lynx1 Capital Management LP.
This page lists
69
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.